Oren Gilad, President/CEO at Aprea Therapeutics, Inc. (APRE), bought 250 shares at $2.90 ($725) on 2024-10-15, disclosed to the SEC on 2024-10-16.
Open-market purchase of $725 APRE by President/CEO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| APRE | BUY | 2024-10-24 | $2K | — | Filing → |
| APRE | BUY | 2024-10-15 | $3K | — | Filing → |
| APRE | BUY | 2024-03-14 | $15K | — | Filing → |